LurexBio treats each platform component as independently protectable, so the estate does not depend on any single filing. Patent counsel Hayes Soloway P.C. is prosecuting a staged filing strategy across the four components, with priority dates established ahead of any public data release.
The four domains are prosecuted as separate innovations rather than one bundled claim, so no single filing carries the whole estate.
The recognition flag itself, and its installation at the tumor surface.
Non-viral delivery: the engineered approach to installing NeoTag™ at the tumor surface.
Safety and activation logic: the programmable controls confining platform activity.
Governing decision architecture: coordination across the other three domains.
Filings are proceeding on published mechanism ahead of experimental results. That sequencing is deliberate: it is what makes the IP estate the most developed part of the program today, even at an early research stage.
Hayes Soloway P.C., with a team of scientist-lawyers, manages the filing calendar and prosecution strategy across the four domains.
What each component actually doesSpecific filing dates and counts go to prospective investors as part of diligence rather than being published here.